ARTICLE | Company News
EntreMed, Allergan, Oculex deal
January 28, 2002 8:00 AM UTC
Under a 5-year deal, the companies will develop and commercialize small molecule angiogenesis inhibitors to treat or prevent ophthalmic disorders. The deal includes ENMD's Panzem 2-methoxyestradiol (...